Patent Issued for Terameprocol and nordihydroguaiaretic acid (NDGA) derivatives as coronavirus anti-viral agents (USPTO 11844768).

A patent has been issued for the use of Terameprocol and nordihydroguaiaretic acid (NDGA) derivatives as anti-viral agents against coronaviruses. The patent describes methods of administering these derivatives to patients infected with or at risk of infection with a coronavirus, including SARS-CoV-2. The derivatives have been found to inhibit viral RNA replication. This patent provides potential treatment options for COVID-19 and other illnesses caused by coronaviruses. [Extracted from the article]